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Puromycin aminonucleoside-induced nephrotic syndrome (PAN-NS) is characterized by cardiac remodeling and increased local
inflammatory activity. Patients with NS and animal models of NS have vitamin D3 deficiency. The aim of the present study was to
evaluate the influence of calcitriol on cardiac remodeling and local inflammatory state in PAN-NS rat model. Male Sprague-Dawley
rats were injected with PAN or vehicle on day 0. PAN and control rats were divided into two subgroups for the administration of
calcitriol (PAN-DandCt-D groups) or the vehicle (PAN-VandCt-V groups) during 21 days.Onday 21, the renal function,metabolic
balance, calcitriol and FGF-23 plasma levels, prohypertrophy and proinflammatorymarkers (ET-1, TGF-𝛽1, TNF-𝛼, and IL-1𝛽), and
calcium signalingmolecules (PLB and SERCA-2a) were evaluated. Twenty-one days after injection, PAN-V group presented cardiac
hypertrophy and a modulation of proinflammatory markers local expression. Calcitriol treatment of PAN rats prevented cardiac
hypertrophy and was associated with marked reduction in the cardiac expression levels of proinflammatory markers. Our results
suggest that vitamin D3 deficiency in PAN-NS may contribute to cardiac remodeling and to the increase in local inflammatory
activity. Calcitriol treatment prevents both cardiac repercussions and local inflammatory processes in PAN-NS.
1. Introduction
The nephrotic syndrome (NS) is characterized by increased
proteinuria, accompanied by hypoalbuminemia, hyperlipi-
demia, lipiduria, and sodium retention that can lead to
edema formation and ascites accumulation [1]. Additionally,
the NS is associated with high incidence of heart diseases
[2, 3]. Although dyslipidemia and hypercoagulability have
been considered main factors implicated in heart disease in
patients with NS [2, 3], other studies suggest that these classic
cardiovascular risk factors cannot account alone for the high
cardiovascular risk and mortality associated with proteinuria
[4, 5].
Previous studies from our group showed that increased
proteinuria in puromycin aminonucleoside-induced-NS
(PAN-NS) rat model is accompanied by cardiac remodeling,
impaired left ventricle function, and elevated cardiac pro-
inflammatory activity [6]. These results suggest that protein
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wasting together with enhanced proinflammatory state may
contribute to an increased cardiovascular risk in patients
with NS.
Proteinuria due to glomerular injury and permeability
dysfunction in NS has been associated with additional com-
plications that result from the loss of vitamin D3 and its
metabolites [1]. Plasma levels of vitamin D3 and metabolites
are also reduced in patients with NS and normal renal func-
tion [7–9], as well as in animalmodels ofNS [10, 11]. Although
these studies provide evidence for a dysfunctional vitaminD3
metabolism in NS, the implications of calcitriol deficiency in
this condition, namely, in the increased cardiovascular risk of
these patients, remain to be elucidated.
Vitamin D3 is a steroid hormone that has a key func-
tion in the regulation of calcium, phosphate, and bone
metabolism [1]. The active metabolite of vitamin D3, cal-
citriol, was suggested to have important beneficial effects
in the cardiovascular system [12, 13]. Vitamin D3 therapy
was described to contribute to increased survival among
patients with chronic kidney disease [12, 14, 15]. Vitamin D
receptor (VDR) knockoutmice and vitaminD3-deficient rats
were shown to have increased myocardial contractility along
with cardiomyocytes hypertrophy and myocardial collagen
accumulation [16].
On the basis of the previous considerations, the aim of
the present study was to evaluate the effects of calcitriol
supplementation on cardiac remodeling and local inflam-
matory activation in PAN-NS. Specifically, we evaluated the
role of calcitriol in cardiac morphology, in the levels of
proinflammatory and prohypertrophy markers (Endothelin-
1 (ET-1), transforming growth factor-𝛽1 (TGF-𝛽1), tumor
necrosis factor-𝛼 (TNF-𝛼), and interleukin-1𝛽 (IL-1𝛽)) and
calcium signaling molecules (Phospholamban (PLB) and
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA-2a)). In
addition, we studied the effect of calcitriol in the renal and
metabolic function of PAN-NS animal model.
2. Materials and Methods
2.1. InVivo Studies. All in vivo investigationswere performed
in accordance with the European Directive number 86/609,
transposed to the Portuguese Law by DL 129/92 and by
Portaria 1005/92.
2.1.1. PAN-Induced Nephrosis. Normotensive male Sprague-
Dawley rats (Harlan Laboratories Inc., Barcelona, Spain),
weighing ∼150 g, were selected after a seven-day period of
stabilization. The animals received a single intraperitoneal
injection (ip) of 10mL/kg body weight (bw) of PAN (Sigma,
St. Louis, MO, USA), 150mg/kg bw (PAN group), or the
vehicle, NaCl 0.9% (control (Ct) group), on day 0.
2.1.2. Calcitriol Treatment. PAN and Ct groups were divided
into two subgroups for the administration of calcitriol
(Sigma), 50 ng/kg bw, ip (PAN-D, 𝑛 = 4; Ct-D, 𝑛 = 4), or
the vehicle, propylene glycol diluted in 0.1% ethanol (v/v), ip
(PAN-V, 𝑛 = 3; Ct-V, 𝑛 = 3). Calcitriol or vehicle was given
daily from day 0 to day 20.
2.1.3. Metabolic Studies and Tissue Collection. The animals
were kept under controlled environmental conditions (12 : 12
hours’ light/dark cycle and room temperature 22 ± 2∘C). Four
days before day zero, the rats were housed in metabolic cages
(Tecniplast, Buguggiate (VA), Italy) for urine collection. In
order to achieve the same daily sodium intake among the
groups, the animals were fed as previously described [17].
Twenty-four-hour urine was collected in empty vials to mea-
sure proteins, calcium, phosphate, creatinine, sodium, and
potassium levels. Animals were sacrificed on day 21 after PAN
or vehicle injection. Blood was collected from the heart in
vials containing lithium/heparin, centrifuged at 3800𝑔 for
15 minutes, and plasma was stored at −80∘C for later deter-
mination of calcium, phosphate, creatinine, sodium, potas-
sium, proteins, alkaline phosphatase (ALP), calcitriol, and
fibroblast growth factor 23 (FGF-23).The heart was collected,
weighed, and dissected: the right and the left ventricles
together with the interventricular septum were separately
weighed.The left ventricle (LV) was divided into several por-
tions, somewere kept in formalin for histological procedures,
and others were frozen at −80∘C for western-blotting and real
time reverse transcription polymerase chain reaction (RT-
PCR). Tibia length was measured for heart weight norma-
lization.
2.2. In Vitro Studies
2.2.1. Plasma and Urine Ionogram and Biochemistry. The
quantification of sodium, potassium, total proteins, creati-
nine, and ALP was assayed in a Cobas Mira Plus analyzer
(ABXDiagnostics, Switzerland) and the creatinine clearance,
fractional excretion of sodium (FENa
+), and sodium balance
were calculated as previously reported [18].
2.2.2. Calcitriol and FGF-23 Determination. Calcitriol and
FGF-23 levels in plasma samples were measured using com-
mercial enzyme-linked immunosorbent assay kits following
the manufacturer’s protocol (Immundiagnostik, Bensheim,
Germany, and Merck Millipore, Billerica, MA, USA, respec-
tively).
2.2.3. Heart Histology. LV samples were fixed in formalin,
sectioned in 4 𝜇m thick slices (Electronic Rotary Microtome
HM 340E, Microm, Thermo Fisher Scientific, Waltham,
MA, USA), and stained with haematoxylin and eosin (H&E
staining) for lightmicroscope visualization (DM4000B, Leica
Microsystems, Wetzlar, Germany). For myocardial hypertro-
phy assessment, the transversal diameter of cardiomyocytes
was double-blindly measured in 70 cells randomly selected
from eight to ten microscopic fields (Leica Application Suite
Software, Leica Microsystems). To assess fibrosis, Sirius red
staining was performed according to standard protocol.
2.2.4. Immunohistochemistry. Left ventricle paraffin’s 4𝜇m
thick slices were deparaffinized, hydrated in alcohol, and
blocked with 3% H2O2 in methanol for ten minutes followed
by incubation with goat anti-rabbit serum (Vectastain ABC
kit, Vector Laboratories, Burlingame, CA, USA) for one
hour at room temperature. Thereafter, slices were incubated
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Table 1: Body weight, metabolic balance, and renal function in control (Ct-V and Ct-D) and nephrotic (PAN-V and PAN-D) rats, after 21
days of calcitriol or vehicle treatments.
Day 21
Ct-V Ct-D PAN-V PAN-D
Body weight (g) 240 ± 3 237 ± 5 205 ± 6∗ 183 ± 5∗,†
Food intake (g/24 h) 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 0.02 ± 0.00
P proteins (g/L) 52.7 ± 3.4 51.4 ± 0.4 48.8 ± 2.6 53.0 ± 2.5
U proteins (mg/24 h) 15.3 ± 2.4 17.0 ± 2.2 358 ± 37∗ 413 ± 53∗
Na+ intake (mmol/24 h) 1.65 ± 0.00 1.65 ± 0.00 1.65 ± 0.00 1.65 ± 0.00
P Na+ (mmol/L) 146 ± 5 149 ± 2 143 ± 3 150 ± 1
U Na+ (mmol/24 h) 1.31 ± 0.23 1.40 ± 0.05 1.38 ± 0.14 1.44 ± 0.09
Na+ balance (mmol/24 h) 0.35 ± 0.23 0.26 ± 0.05 0.27 ± 0.14 0.21 ± 0.09
FE Na+ (%) 0.34 ± 0.07 0.67 ± 0.23 0.57 ± 0.10 0.60 ± 0.16
P Ca2+ (mmol/L) 2.45 ± 0.15 3.13 ± 0.08∗ 2.84 ± 0.47 3.03 ± 0.09
U Ca2+ (mmol/24 h) 0.26 ± 0.12 0.04 ± 0.02 0.01 ± 0.00 0.02 ± 0.01
FE Ca2+ (%) 4.57 ± 3.00 3.58 ± 1.77 0.17 ± 0.03 0.52 ± 0.20
P P (mmol/L) 2.96 ± 0.24 3.33 ± 0.39 3.10 ± 0.23 3.52 ± 0.16
U P (mmol/24 h) 0.06 ± 0.04 0.12 ± 0.03 0.08 ± 0.05 0.10 ± 0.03
FE P (%) 0.53 ± 0.23 1.37 ± 0.43 0.43 ± 0.21 1.27 ± 0.26
P creatinine (mg/L) 3.73 ± 0.29 5.07 ± 0.58 4.70 ± 0.59 3.27 ± 0.61
C creatinine (mL/min) 2.44 ± 0.74 1.76 ± 0.15 1.49 ± 0.27 1.75 ± 0.59
P ALP (U/I) 147 ± 23 141 ± 8 101 ± 21 98 ± 8∗
Values are means ± SE; 푛 = 3 to 4 experiments per group. P, plasma; U, urine; FE, fractional excretion; and C, clearance. ∗푃 < 0.05, significantly different from
values in the corresponding control groups (Ct-V or Ct-D); †푃 < 0.05, significantly different from corresponding values in PAN-V group.
with primary antibodies overnight at 4∘C: rabbit polyclonal
anti-TGF-𝛽1 (1/50, Santa Cruz Biotechnology, Inc., Dallas,
Texas, USA) and rabbit polyclonal anti-ET-1a (1/100, Santa
Cruz Biotechnology Inc.). Immunostaining was detected
using an anti-rabbit secondary biotinylated antibody (Diluted
1/100, Vector Laboratories) combined with an avidin-biotin
complex (Vectastain ABC kit, Vector Laboratories), followed
by 97% 3,3耠-diaminobenzidine tetrahydrochloride hydrate
(Sigma) and hematoxylin counterstaining.
2.2.5. Western-Blotting. Primary antibodies used for protein
detection were the following: mouse polyclonal anti-𝛽-actin
(1/20,000 Santa Cruz Biotechnology, Inc.), mouse mono-
clonal anti-TNF-𝛼 and anti-IL-1𝛽 (1/50, R&D Systems, 614
McKinley Place NE, MN, USA), mouse polyclonal anti-PLB
(1/200, Affinity Bioreagents, Thermo Fisher Scientific), and
rabbit polyclonal anti-SERCA-2a (1/1000, Cyclacel Pharma-
ceuticals Inc. Berkeley, Heights, NJ, USA). Left ventricle sam-
ples were homogenized with lysis buffer supplemented with
phosphatase and protease inhibitors (Pierce Biotechnology,
Thermo Fisher Scientific) solubilized in sample buffer [19]
and denatured at 95∘C for five minutes. Total proteins (30 𝜇g
per well) were separated by sodium dodecyl sulfate polyacry-
lamide gel electrophoresis (12% acrylamide) and transferred
onto a nitrocellulose membrane (Bio-Rad Laboratories, Inc.,
Hercules, CA, USA). Membranes were blocked with 5%
nonfat dry milk in phosphate buffered saline containing 0.1%
Tween 20, incubated with the primary antibodies overnight
at 4∘C, and lastly incubated for one hour at room temper-
ature with fluorescently labelled goat anti-mouse (1/30,000
IRDye700, Rockland Immunochemicals, Inc., Pottstown, PA,
USA) or donkey anti-rabbit (1/20,000, IRDye800, Rockland
Immunochemicals, Inc.). Primary antibody binding was
assessed by scanning the membranes with the Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln, NE,
USA) and the intensity values were normalized for 𝛽-actin
and shown as percentage of mean density of control rats.
2.2.6. Real Time RT-PCR. mRNA expression quantification
of pre-pro-ET-1, TGF-𝛽1, SERCA-2a, PLB, TNF-𝛼, IL-1𝛽, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes
in left ventricle samples was performed by real time RT-PCR
as previously reported [20].
2.3. Statistics. Results are means ± SEM of values for the
indicated number of determinations and were compared by
one-way ANOVA followed by Student’s t-test for unpaired
comparisons. 𝑃 < 0.05 was assumed to denote a significant
difference.
3. Results
3.1. Characterization of PAN Nephrosis. Renal function and
other markers of metabolic balance are described in Table 1
for control (Ct-V andCt-D) and nephrotic (PAN-V and PAN-
D) rats, after 21 days of calcitriol or vehicle treatments. The
protein excretion remained elevated in PAN rats up to 21
days after PAN injection (Figure 1). At this stage, the urinary
Na+ excretion and the FENa
+ were similar among groups,
indicating that the animals had reached a status of Na+
balance (Figure 1 and Table 1). Albeit all animals had the same
food intake throughout the study, the bodyweight of PANrats
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Figure 1: (a) Histomorphometry of the left ventricle in control (Ct-V and Ct-D) and nephrotic (PAN-V and PAN-D) rats, after 21 days
of calcitriol (D) or vehicle (V) treatments. Cardiomyocytes cell size was determined by double-blind measure of the smallest transversal
diameter. Data were obtained from 70 cells randomly selected from 8–10 microscopic fields. ∗𝑃 < 0.05 versus Ct-V rats; †𝑃 < 0.05 versus
PAN-V rats. (b) Light microscopy images of left ventricle cardiomyocytes from Ct-V, Ct-D, PAN-V, and PAN-D rats, 21 days after PAN or
vehicle injection. Sections were stained with H&E (magnification 200x).
was significantly reduced in comparison to the corresponding
control groups at the end of the study (Table 1).
Fractional excretion of Ca2+ (FECa2+) was reduced in
PAN rats in comparison to the corresponding control group,
although no statistical significance was observed (Table 1).
Fractional excretion of P (FE P) and creatinine clearancewere
similar among the four groups (Table 1).
3.2. Cardiac Morphology and Histomorphometry. Twenty-
one days after PAN injection, we observed a cardiac hypertro-
phy, evidenced by increased heart weight/tibial length ratio
and LV/tibial length ratio (Table 2), as well as increased
cardiomyocytes diameter (Figures 1(a) and 1(b)). Calcitriol
treatment significantly reverted the increased cardiomy-
ocytes diameter in PAN-treated group (Figure 1) but not the
heart weight/tibial length ratio and the LV/tibial length ratio
(Table 2).
3.3. Cardiac Calcium-Handling Molecules. PLB gene expres-
sion was significantly reduced by PAN injection but not
influenced by calcitriol supplementation (Figure 2). A similar
profile was observed in PLB protein expression, but without
statistical significance.
Twenty-one days after PAN or vehicle injection, LV
gene expression of PLB was significantly reduced in PAN-
treated groups (PAN-V and PAN-D) in comparison to their
corresponding controls (Ct-V and Ct-D) (Figure 2(a), left
panel). However, no significant differences were observed
in LV protein expression of PLB among the four groups
(Figure 2(a), right panel).
PAN animals treated with calcitriol showed significantly
reduced gene expression of SERCA-2a in LV in comparison
to the control group Ct-D (Figure 2(b), left panel).
3.4. Cardiac Hypertrophy and Proinflammatory Activity. No
significant difference was found in pre-pro-ET1 gene expres-
sion in LV between Ct-V and Ct-D groups (Figure 3(a)).
Twenty-one days after PAN or vehicle injection, PAN-V
group presented a 2.5-fold increase of pre-pro-ET1 gene
expression in the LV in comparison with Ct-V group
(Figure 3(a)). By contrast, PAN rats treated with calcitriol
presented pre-pro-ET1 LV gene expression levels similar to
those observed in the corresponding control group (Ct-D)
(Figure 3(a)). Figure 3(b) illustrates immunohistochemistry
images of ET-1a in LV paraffin sections of the four groups of
animals. Amarked increase in the protein expression of ET-1a
was observed in the LV of PAN-V group in comparison with
both Ct-V and PAN-D groups.
No significant difference was found in TGF-𝛽1 gene
expression in LV between Ct-V and Ct-D groups (Fig-
ure 4(a)). Twenty-one days after PAN or vehicle injection,
PAN-V group presented a 2-fold increase of TGF-𝛽1 gene
expression in the LV in comparison with Ct-V group (Fig-
ure 4(a)). By contrast, PAN rats treated with calcitriol
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Table 2: Characterization of cardiac morphometry in control (Ct-V and Ct-D) and nephrotic (PAN-V and PAN-D) rats, after 21 days of
calcitriol (D) or vehicle (V) treatments.
Day 21
Ct-V Ct-D PAN-V PAN-D
Heart weight (mg) 923.3 ± 5.0 940.3 ± 27.2 960.0 ± 8.9∗ 933.8 ± 18.8
Heart weight/tibial length (mg/mm) 245.3 ± 4.8 249.9 ± 9.7 269.2 ± 1.8∗ 262.9 ± 6.2
LV weight/tibial length (mg/mm) 173.6 ± 7.0 178.8 ± 7.0 198.7 ± 6.2∗ 196.2 ± 3.2
RV weight/tibial length (mg/mm) 37.1 ± 1.7 40.2 ± 1.5 34.9 ± 1.5 31.6 ± 1.6
Values are means ± SE; 푛 = 3 to 4 experiments per group; LV, left ventricle; RV, right ventricle; ∗푃 < 0.05, significantly different from corresponding values in
Ct-V group.
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Figure 2: (a) Top: left ventricle mRNA and protein expression of total PLB in control (Ct-V and Ct-D) and nephrotic (PAN-V and PAN-D)
rats, after 21 days of calcitriol (D) or vehicle (V) treatments. mRNA and protein expression were normalized for GAPDH gene and 𝛽-actin
protein, respectively. Results are expressed as % of control. ∗𝑃 < 0.05 versus correspondent control rats. Bottom: representative immunoblots
of PLB (pentamer 25KDa and monomer 10KDa bands) and 𝛽-actin (43KDa band). (b) Top: left ventricle mRNA and protein expression
of SERCA-2a in control (Ct-V and Ct-D) and nephrotic (PAN-V and PAN-D) rats, after 21 days of calcitriol (D) or vehicle (V) treatments.
mRNA and protein expression were normalized for GAPDH gene and 𝛽-actin protein, respectively. Results are expressed as % of control.
∗𝑃 < 0.05, versus Ct-V group. Bottom: representative immunoblots of SERCA-2a and 𝛽-actin (110 KDa and 43KDa bands, respectively).
presented TGF-𝛽1 LV gene expression levels similar to
those observed in the corresponding control group (Ct-D)
(Figure 4(a)). Figure 4(b) illustrates immunohistochemistry
images of TGF-𝛽1 in LV paraffin sections of the four groups
of animals. In agreement with previous results, a marked
increase in protein expression of TGF-𝛽1 was observed in
the LV of PAN-V group in comparison with both Ct-V and
PAN-D groups. Microscopy images of Sirius red staining
were obtained to visualize cardiac fibrosis (red color denotes
connective tissue staining). As can be observed in Figure 4(c),
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Figure 3: (a) Left ventricle mRNA expression of pre-pro-ET1 in control (Ct-V and Ct-D) and nephrotic (PAN-V and PAN-D) rats, after 21
days of calcitriol (D) or vehicle (V) treatments. mRNA expression was normalized for GAPDH gene and the results are expressed in % of
control. ∗𝑃 < 0.05 versus Ct-V rats; †𝑃 < 0.05 versus PAN-V rats. (b) Immunohistochemical detection of ET-1a in left ventricle of control
(Ct-V and Ct-D) and nephrotic (PAN-V and PAN-D) rats, after 21 days of calcitriol (D) or vehicle (V) treatments (magnification 200x).
PAN-V rats presented stronger staining for connective tissue
in the LV in comparison with vehicle-treated rats (Ct-V, Fig-
ure 4(c)). In PAN rats treated with calcitriol, the connective
tissue staining was markedly attenuated in comparison to
PAN-V group (Figure 4(c)).
TNF-𝛼 mRNA levels in the LV did not differ among
the four groups (Figure 5(a), left panel). By contrast, TNF-𝛼
protein expression was elevated in PAN-V rats in comparison
toCt-V group (Figure 5(a), right panel). PAN rats treatedwith
calcitriol (PAN-D) presented levels of TNF-𝛼 protein expres-
sion similar to those found in the corresponding control
group (Ct-D) (Figure 5(a), right panel). No significant differ-
ences were observed in IL-1𝛽 protein and gene expression in
the myocardial tissue, among the four groups (Figure 5(b)).
3.5. Calcitriol and FGF-23 Plasma Levels. Calcitriol plasma
levels were reduced in both Ct and PAN groups of rats
treated with calcitriol (Figure 6, left panel). In addition,
calcitriol plasma levels were significantly reduced in PAN rats
treated with calcitriol in comparison with the corresponding
control group (Ct-D). By contrast, FGF-23 plasma levels were
significantly increased in calcitriol-treated rats in both Ct and
PAN groups (Figure 6, right panel).
4. Discussion
In the present study, we evaluated the influence of calcitriol
supplementation on cardiac remodeling and enhanced local
inflammatory activity in PAN-NS rat model. Calcitriol sup-
plementation in PAN-NS prevented cardiac hypertrophy,
fibrosis, and inflammation, namely, by downregulating ET-
1a, TGF-𝛽1, and TNF-𝛼 genes and protein expression. Taken
together, our results suggest that calcitriol supplementation
has important beneficial effects in the myocardial dysfunc-
tion observed in NS.
Previous results from our group, obtained seven and
fourteen days after PAN injection, demonstrated that cardiac
remodeling and dysfunction are accompanied by cardiac
inflammatory activation [20]. In the present study, we show
that 21 days after PAN injection, the nephrotic animals
maintain a dysregulated myocardial structure and function
evidenced by cardiomyocytes hypertrophy, elevated fibrosis,
and enhanced proinflammatory activity. The current study
evaluated the effect of daily treatment with calcitriol for
21 days in cardiac dysfunction displayed by PAN-NS rats.
Calcitriol supplementation to nephrotic animals during 21
days prevented the increase of both the ET-1a and TGF-
𝛽1 levels observed in the nephrotic control group. These
findings together with the reduction of connective tissue
staining observed in the left ventricle of PAN rats treated with
calcitriol indicate a protective effect of calcitriol in cardiac
hypertrophy and fibrosis.
Previous reports state that cardiac myocytes have a
functional vitamin D3 system that plays an important role
as an antihypertrophic agent [21, 22]. Calcitriol or its non-
hypercalcemic analogues were suggested to antagonize ET-1a
BioMed Research International 7
Ct-V Ct-D PAN-V PAN-D
∗
0
50
100
150
200
250
TG
F-

1
/G
A
PD
H
 (%
 o
f c
on
tro
l)
(a) Gene expression
Ct-V Ct-D PAN-V PAN-D
(b) Protein expression
Ct-V Ct-D PAN-V PAN-D
(c) Sirius red staining
Figure 4: (a) Left ventricle mRNA expression of TGF-𝛽1 in control (Ct-V and Ct-D) and nephrotic (PAN-V and PAN-D) rats, after 21 days
of calcitriol (D) or vehicle (V) treatments. mRNA expression was normalized for GAPDH gene and the results are expressed in % of control.
∗𝑃 < 0.05, versus Ct-V rats. (b) Immunohistochemical detection of TGF-𝛽1 in left ventricle of control (Ct-V and Ct-D) and nephrotic
(PAN-V and PAN-D) rats, after 21 days of calcitriol (D) or vehicle (V) treatments (magnification 200x). (c) Sirius red staining illustrating
fibrosis significantly increased in PAN-V rats in comparison to Ct-V and PAN-D rats, after 21 days of calcitriol (D) or vehicle (V) treatments
(magnification 200x).
induced hypertrophy in vitro by modulating the expression
of hypertrophy regulatory genes [23]. Additionally, spon-
taneously hypertensive heart failure rats that were fed a
high-salt diet and treated with calcitriol presented lower
heart weight and left ventricular diameter, thus suggesting
that calcitriol behaves as an antihypertrophy factor [22].
Mesenchymalmultipotent cells treatedwith calcitriol showed
increased expression of VDR and antifibrotic factors and
decreased expression of TGF-𝛽1 and collagen types I and
III [24]. Collectively these findings together with our results
lead to the hypothesis that vitamin D3 deficiency in PAN-NS
may contribute to cardiac dysfunction due to an exacerbated
hypertrophic state.
The local production of proinflammatory factors such
as TNF-𝛼 in the heart is potentially relevant due to the
well-known effects on cardiac remodeling and contractile
dysfunction [25, 26]. Furthermore, patients with focal seg-
mental glomerular sclerosis presented higher TNF-𝛼 plasma
and urine levels in comparison to those registered by healthy
controls [27]. In line with this, peripheral bloodmononuclear
cells isolated from patients with primary nephrotic syndrome
showed enlarged TNF-𝛼 production in comparison with
controls [28]. Although the urinary or systemic levels of TNF-
𝛼 were not assessed in this study, we observed a marked
increase in the cardiac levels of TNF-𝛼 protein expression.
Interestingly, the increased expression of TNF-𝛼 observed in
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Figure 5: (a) Top: left ventricle mRNA and protein expression of TNF-𝛼 in control (Ct-V and Ct-D) and nephrotic (PAN-V and PAN-D)
rats, after 21 days of calcitriol (D) or vehicle (V) treatments. mRNA and protein expression were normalized for GAPDH gene and 𝛽-actin
protein, respectively. Results are expressed as % of control. ∗𝑃 < 0.05 versus Ct-V rats. Bottom: representative immunoblots of TNF-𝛼 and 𝛽-
actin (25 KDa and 43KDa bands, respectively). (b) Top: left ventricle mRNA and protein expression of IL-1𝛽 in control (Ct-V and Ct-D) and
nephrotic (PAN-V and PAN-D) rats, after 21 days of calcitriol (D) or vehicle (V) treatments. mRNA and protein expression were normalized
for GAPDH gene and 𝛽-actin protein, respectively. Results are expressed as % of control. Bottom: representative immunoblots of IL-1𝛽 and
𝛽-actin (31 KDa and 43KDa bands, respectively).
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the nephrotic animals was prevented by the administration of
calcitriol. Our results are in accordance with a previous study
whereby humanmonocytes stimulated by interferon or phor-
bol esters displayed an impaired production of TNF-𝛼 [29].
Although IL-1𝛽was described to be amajor proinflammatory
mediator in children with nephrotic syndrome and in animal
models of nephrosis [30–32], in the present study no varia-
tions were observed in IL-1𝛽 expression levels in PAN-treated
rats compared to the control group. Likewise, calcitriol did
not exert any action on this proinflammatory cytokine.
SERCA-2a is the main protein involved in calcium
reuptake into the sarcoplasmic reticulum of cardiomyocytes
and the modulation of its activity is dependent on PLB
phosphorylation [33]. In our previous study [20], seven and
fourteen days after PAN injection, nephrotic rats presented
reduced cardiac protein levels of both SERCA-2a and PLB;
however, at 21 days after PAN injection, no major alterations
were observed in these protein levels. These findings suggest
that, on a later stage of the animal model of PAN-NS,
SERCA-2a and PLB may not be important contributors to
myocardial dysfunction. Although vitamin D3 was shown
to be involved in the contractile function of the heart by
regulating calcium cycling in adult myocytes [34], herein
calcitriol supplementation appears not to be a relevant factor
in the regulation of PAN-NS-calcium signaling.
Patients with NS as well as nephrotic rats are known
to have vitamin D3 deficiency due to loss in urine as a
result of impaired renal function [7, 10]. In the present
study, the supplementation with calcitriol was expected to
induce a raise in calcitriol blood levels. However, after
21 days of calcitriol daily supplementation (at the end of
the experiment), we unexpectedly observed a noteworthy
reduction in the calcitriol blood levels in both control and
nephrotic animals. Yadav et al. showed that FGF-23 is reduced
in subjects with untreated nephrotic syndrome and suggested
that the reduced levels of vitamin D and urinary losses may
contribute to lower levels of FGF-23 in NS [35]. Interestingly,
in our study, calcitriol treatment leads to a significant increase
in FGF-23 plasma levels in both control and nephrotic
animals. In addition, although the food intake was equivalent
in all groups, calcitriol-treated animals presented slightly
higher phosphaturia in comparison to vehicle-treated rats.
The main physiological function of FGF-23 is to stimulate
phosphaturia and thereby reduce calcitriol levels. In order
to do that, FGF-23 acts by inhibiting renal 1𝛼-hydroxylase
and stimulating 24-hydroxylase [36]. Chronic kidney disease
patients have reduced viable nephrons and elevated FGF-
23 which impairs activation of 1𝛼-hydroxylase and therefore
leads to low serum levels of 25-hydroxy vitamin D and
consequently calcitriol [36]. Our results show a rise in FGF-
23 plasma levels in response to calcitriol supplementation in
order tomaintain phosphate homeostasis in calcitriol-treated
rats.
In summary, our results show that calcitriol supplemen-
tation to PAN-NS rats prevents cardiovascular remodeling
and enhanced left ventricle inflammatory activity, namely, by
preventing cardiomyocytes hypertrophy and by decreasing
gene and protein expression of several proinflammatory
molecules. These findings suggest that vitamin D3 system
may be endowed with an important protective role in cardiac
remodeling and dysfunction in NS.
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